Investing.com - Leap Therapeutics reported on Monday third quarter earnings that missed analysts' forecasts and revenue that was inline with expectations.
Leap Therapeutics announced earnings per share of $-0.1300 on revenue of $0.00. Analysts polled by Investing.com EPS of $-0.1200 on revenue of $0.00.
Leap Therapeutics 's are down 45% and is trading at $0.6949 , still down 79.85% from its 52 week high of $3.45 set on Monday, January 3, 2022.
Leap Therapeutics shares gained 10.99% to trade at $0.6949 in intra-day trade the report.
Leap Therapeutics follows other major Healthcare sector earnings this month
Leap Therapeutics's report follows an earnings beat by J&J on Tuesday, October 18, 2022, who reported EPS of $2.55 on revenue of $23.79B, EPS of $2.48 on revenue of $23.36B.
Eli Lilly had beat expectations on Tuesday, November 1, 2022 with third quarter EPS of $1.98 on revenue of $6.94B, for EPS of $1.91 on revenue of $6.91B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar